skip to Main Content

COMBAT Study Preliminary Results Show Response of 32% in Treatment of Pancreatic Tumors

COMBAT Study Preliminary Results Show Response of 32% in Treatment of Pancreatic Tumors
Working with an international team of researchers, HonorHealth Research Institute and the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, were instrumental in one of the first clinical trials showing how pancreatic cancer patients can benefit from immunotherapy, according to a four-year study published in a premier scientific journal, Nature Medicine.

The “COMBAT trial” (NCT02826486) is a prospective, open label, phase IIa clinical trial for patients with metastatic pancreatic cancer, meaning their cancer had spread to other parts of the body. Read more . . . 


Back To Top